With the increasing ease of isolating monoclonal antibodies (MAbs) comes the growing challenge of engineering, differentiating, and patenting them for therapeutic development. Here we will discuss emerging approaches to integrate lab-based approaches with modern molecular and AI-based tools to create novel and differentiated antibody therapeutics. At Integral Molecular, comprehensive CDR-scanning is now routinely used to test every variant of an antibody for parallel, multi-parameter engineering of affinity, developability, and specificity. AI/ML-based tools are then used to rapidly design final therapeutic candidates, including MAbs against the most difficult targets in the industry, GPCRs, ion channels, and transporters.